Compare Abeona Therapeutics Inc (ABEO) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Emerson Electric Co. — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Emerson Electric Co. trades at $164.49 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 217.7× Abeona Therapeutics Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EMR | |
|---|---|---|
Market Cap | $421.19M | $91.69B |
Sector | Health | Industrials |
52-Week High | $7.45 | $164.38 |
52-Week Low | $4.17 | $123.30 |
Enterprise Value | $276.10M | $102.77B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Emerson Electric (EMR) trades at $164.56, up 3.7% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock exhibits a bullish technical setup, with key resistance at $168, while fundamentals show solid revenue growth and a 13.83% net income margin. Recent news highlights Q3 2026 results exceeding expectations, driven by 7% organic growth and strategic acquisitions like Glue Inc. to bolster AI capabilities in test and measurement.
Outlook remains positive with raised 2026 guidance, though valuation multiples like a P/E of 35.97 suggest premium pricing. Risks include execution challenges in integrating acquisitions and macroeconomic pressures on industrial demand. Analyst consensus favors Buy ratings with a $171.33 price target, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
